SCHEMBL30834657

SCHEMBL30834657

CC(C)(C)OC(=O)N1CCN2c3ccc(Br)cc3OC[C@H]2C1

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 5/20 0.42
FPR2 P25090 3/20 0.42
BACE1 P56817 6/20 0.41
SMARCA2 P51531 1/20 0.39
SMARCA4 P51532 1/20 0.39
PBRM1 Q86U86 1/20 0.39
SOS1 Q07889 1/20 0.38
RORC P51449 2/20 0.37
HDAC6 Q9UBN7 1/20 0.37
SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30834647 1.00 USP30 (0.42) USP30FPR2BACE1SMARCA2SMARCA4
SCHEMBL30834655 1.00 USP30 (0.42) USP30FPR2BACE1SMARCA2SMARCA4
SCHEMBL31580347 0.92 USP30 (0.42) USP30FPR2BACE1RORC
SCHEMBL31580719 0.92 USP30 (0.42) USP30FPR2BACE1RORC
SCHEMBL31582194 0.92 USP30 (0.42) USP30FPR2BACE1SMARCA2SMARCA4
SCHEMBL4409882 0.88 FPR2 (0.43) USP30FPR2BACE1SMARCA2SMARCA4
SCHEMBL24584057 0.87 NR1H2 (0.45) USP30SMARCA2SMARCA4PBRM1SOS1
SCHEMBL19021651 0.87 NR1H2 (0.45) USP30SMARCA2SMARCA4PBRM1SOS1
SCHEMBL19021797 0.87 NR1H2 (0.45) USP30SMARCA2SMARCA4PBRM1SOS1
SCHEMBL31458525 0.87 NR1H2 (0.45) USP30SMARCA2SMARCA4PBRM1SOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025102600-A1 NOVEL HETEROCYCLIC COMPOUND 首药控股(北京)股份有限公司 2025-05-22 WO disclosed
CN-117886881-A Chimeric compound for targeted degradation of BCL-2 protein, preparation method and application thereof in medicine 江苏恒瑞医药股份有限公司 2024-04-16 CN disclosed
WO-2024067818-A1 CHIMERIC COMPOUND USED FOR TARGETED DEGRADATION OF BCL-2 PROTEIN, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF 江苏恒瑞医药股份有限公司 2024-04-04 WO disclosed